Interview with Dr. Ian S. Zagon, Distinguished University Professor, Department of Neural and Behavioral Sciences, The Pennsylvania State University Schoold of Medicine

Topic: The Discovery of Low Dose Naltrexone

What first led you into your work on Low Dose Naltrexone (LDN)?

Around 1975, I was interested in the effects of exogenous opioids (opiates from external sources, such as heroin, methadone or morphine) on children who were born to mothers that were addicted. The scientific literature revealed that these babies and children had neurological difficulties and were lower in body weight. We (myself and Dr. Patricia McLaughlin) developed a model to look at this in animals. At the same time, I was also conducting another research project into neuroblastoma, a childhood tumor. When I found that these exogenous opioids altered the growth of developing animals, I decided to see if they could also depress the growth of cancer. And, lo and behold, experiments conducted around 1977-1978 in tissue culture revealed that they did! We then investigated whether exogenous opioids would repress growth of the real cancers in mice. And, once again, they did!

Interview with Dr. Maira Gironi, Institute of Experimental Neurology (INSPE) and Department of Neurology, San Raffaele Scientific Institute, Milan, Italy

Topic: LDN As A Potential Treatment For Multiple Sclerosis

What gave you the initial idea that LDN might be effective in multiple sclerosis?

LDN has been thought to trigger prolonged release of beta-endorphins (BE) – endogen opioids exerting several influences on the immune system. In addition, this opioid has shown to interact at different levels with the endocannabinoid system. This finding drove us to speculate that both the symptomatic effect (i.e. on spasticity) and the cannabinoid-mediated neuroprotection (extensively documented by literature) could be co-shared by BE and by a drug increasing their level, such as LDN.

Interview with Dr. Jarred Younger, Instructor in the Department of Anesthesia at Stanford University School of Medicine

Topic: The Use of Low Dose Naltrexone in Fibromyalgia

What gave you the initial idea that LDN might be effective in fibromyalgia?

Two different sources of information lead me to try LDN in a clinical trial for the treatment of fibromyalgia. First, a growing collection of basic science studies (by investigators such as Drs. Linda Watkins and Mark Hutchinson) suggested that naltrexone can reduce the excitability of microglia in the brain, preventing the release of inflammatory and neurotoxic chemicals. Second, a small number of physicians have been using LDN for many years to treat conditions such as fibromyalgia. Bringing these two sources of information together, I hypothesized that LDN would show efficacy over placebo in a clinical trial.

Interview with Moshe Rogosnitzky, Director of Research, MedInsight^® Research Institute

Topic: The Use of OGF in Clinical Practice for Treating Cancer

How did you learn about OGF?

I first learned about OGF while scouring medical literature in search of non-toxic cancer therapies. I came across a lot of potential therapies, but many of them, upon closer inspection, turned out to either be too toxic or over-hyped or over-sold and of little clinical potential. I started investigating potential therapies in greater detail by travelling to the institutions where the research was being carried out and gaining a first-hand impression of the science, the integrity of the researchers, and more. It was sometime in 2001 or 2002 that I travelled to Hershey Medical Center in Pennsylvania to meet Dr. Zagon and explore his inventions in person.

Interview with Dr. Ian S. Zagon, Distinguished University Professor, Department of Neural and Behavioral Sciences, The Pennsylvania State University Schoold of Medicine

Topic: The Discovery of OGF

Coming Soon...